Strong pipeline underpins AbbVie’s dividend

Article Excerpt

AbbVie’s earnings will likely drop 20% in 2023 as its main drug, Humira, faces new competition in the U.S. from generics. However, the company has several promising drugs in its development pipeline that should spur its revenue and earnings for years to come. That should let AbbVie keep raising your dividend, as it has done each year since becoming a separate firm in 2013. ABBVIE INC. $151 is a buy. The company (New York symbol ABBV; High-Growth Dividend Payer Portfolio, Manufacturing sector; Shares outstanding: 1.8 billion; Market cap: $271.8 billion; Dividend yield: 3.9%; Dividend Sustainability Rating: Above Average; www.abbvie.com) makes biopharmaceuticals, with leading positions in immunology, oncology, aesthetics, neuroscience and eye care. AbbVie took its current form on January 3, 2013, when Abbott Laboratories (New York symbol ABT) split into two publicly traded firms. The company last raised your quarterly dividend with the February 2023 payment. Investors now receive $1.48 a share, up 5.0% from $1.41. The new annual rate of $5.92 yields a high 3.9%. Since…